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Case Presentation

A 57 year-old Caucasian male was initially admitted to Methodist
Hospital from an outside hospital for dehydration, increased
heart rate, and weight loss. He has a past medical history of
coronary artery disease status post myocardial infarction and
coronary artery bypass graft, congestive heart failure, paroxysmal
atrial fibrillation on coumadin, diabetes type II on insulin, and
an orthotopic liver transplant in 1997 for end-stage liver disease
secondary to hepatitis C virus and alpha-1 antitrypsin disorder.
At the outside hospital, his one-month hospital course was
complicated by acute on chronic renal failure which warranted
hemodialysis, anemia that required transfusions, MRSA line
sepsis from his Perm-A-Cath treated with vancomycin, and
pneumonia, which was possibly secondary to aspiration. The
patient was transferred to our facility for further management.

He continued to have intermittent fevers, shortness of breath,
a non-productive cough, and hypoxia that required oxygen
therapy. Prior to this prolonged hospitalization, the patient was
able to breath on room air. Serial chest radiographs showed
increasing pulmonary infiltrates despite treatment with a
triple antibiotic regimen. At this time, physical exam was only
remarkable for bibasilar, course crackles, but no wheezes or
rhonchi. He had a trans-thoracic echocardiogram that was
negative for endocarditis, a CT of the abdomen and pelvis that
was negative for abscess, and a chest CT that showed persisting
bilateral lower lobe pulmonary opacities, left greater than right,
and scattered abnormal mediastinal lymph nodes (Figure 2).
Cultures were negative since his episode of E. coli bacteremia,
and labs were unremarkable.

Additional past medical history is significant for hyperlipidemia,
depression and C3 to C5 fracture. Additional surgeries include
AICD placement, a C3 to C4 diskectomy, cholecystectomy and
appendectomy. Social history was negative for alcohol and
substance abuse, but positive for a 30 pack year smoking history,
which he quit one year ago. Family history was significant for
diabetes, coronary artery disease and lung cancer. Current
medications included amiodarone, aspirin, carvedilol, nexium,
zetia, insulin, nebulizers, sirolimus, vancomycin, zosyn, and
gentamicin. His only allergy was to meperidine.
Initial vital signs were temperature 98.9˚ Fahrenheit, pulse 77
beats/minutes, respirations 16 breaths/minute, blood pressure
126/70 mm Hg, oxygen saturation 99 % on room air. The patient
was in no acute distress. Physical exam was significant only for
bilateral crackles at the lung bases, multiple skin tattoos, a rightsided Perm-A-Cath in the chest that was non-tender without
surrounding erythema or swelling, and a surgical scar in the
right upper quadrant.
Chest radiograph on admission showed a right lower lobe
consolidation, and he was continued on antibiotics for presumed
pneumonia. The patient appeared to be improving after
finishing his course of antibiotics for line sepsis and suspected
pneumonia, and plans were made to transfer him to a subacute
rehab with outpatient dialysis. One week after hospital transfer,
he developed fevers and chills with accompanying shortness of
breath. Blood cultures grew out pan-sensitive E. coli from his
Perm-A-Cath. The catheter was removed and a Shiley catheter
was placed. After completing a course of antibiotics, he remained
afebrile, and when his blood cultures showed no growth for 48
hours, another Perm-A-Cath was placed. However, he became
febrile again. A repeat chest radiograph showed increasing left
lingular pneumonia in addition to an unchanged right lower
lobe consolidation (Figure 1). At this point, he finished a course
of empiric moxifloxacin which was recommended by the
infectious disease service.
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Figure 1. Chest radiograph shows persistent, asymetric,
bilateral parenchymal infiltrates without change from two
weeks prior. No effusions noted.
A bronchoscopy showed normal airways and no endobronchial
lesions. Biopsies and bronchial alveolar lavage (BAL) were
taken from the superior segment of the left lingua. The BAL
revealed numerous foamy, hemosiderin-laden macrophages,
and the biopsy revealed interstitial pneumonitis consistent with
amiodarone-induced lung toxicity. Stains were negative for
malignant cells.
Amiodarone and antibiotics were stopped, and the patient was
started on prednisone 50 mg PO once daily (1mg/kg/day) with
a taper to 20 mgs per day as his infiltrates cleared. Within one
week of treatment, his fevers resolved with near resolution of
his respiratory symptoms by the time of transfer to rehab. His
vasculitis labs including ANCA, ANA, ESR, double-stranded
DNA, anti-Jo, RF, anti-GBM and IgA, were negative. Further tests
for Legionella, AFB, respiratory viruses, hepatitis B, HIV, CMV,
and EBV were negative. In regards to his atrial fibrillation, since
amiodarone was discontinued, his carvedilol was increased, and
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Figure 2. Chest CT shows persistent bilateral lower lobe
pulmonary opacities, left greater than right, extending to the
periphery.

Figure 3. Two month follow-up chest CT shows resolving
infiltrates and ground glass opacities.

the patient remained in sinus rhythm throughout the rest of his
hospitalization.

for atrial fibrillation and acute management of sustained
ventricular tachyarrythmias.2 It can have a prophylactic role
during the perioperative period of cardiac surgery and may be
an effective adjunct to implantable cardioverter-defibrillator
therapy to reduce the number of shocks. However, adverse
side effects are common and include corneal microdeposits
(>90%), optic neuropathy/neuritis (<1% to 2%), blue-gray
skin discoloration (4% to 9%), photosensitivity (25% to 75%),
hypothyroidism (6%), hyperthyroidism (0.9% to 2%), peripheral
neuropathy(0.3%), hepatotoxicity (15% to 30%), hepatitis and
cirrhosis (<3%), and pulmonary toxicity (1% to 7%).2

A follow-up chest CT two months later revealed significant
improvement of his infiltrates and ground glass opacities.

Discussion

Although amiodarone is approved by the Food and Drug
Administration only for refractory ventricular arrhythmias,
it is one of the most frequently prescribed antiarrhythmic
medications in the United States.1 According to a large evidencebased review, amiodarone has clinical value in patients with left
ventricular dysfunction and heart failure as first-line treatment
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Amiodarone was initially developed in the 1960s as an antianginal
agent due to its vasodilatory properties and serendipitously
was found to suppress arrythmias. Despite widespread use for
nearly two decades in Western Europe, there were no reported
cases of associated pulmonary toxicity until 1980, after it was
introduced as an investigational agent in this country. This
was initially thought to be due to the higher doses used for
ventricular arrythmias,3 but retrospective analysis revealed that
cases had been observed in Europe, but were missed. Currently,
amiodarone-induced pulmonary toxicity (APT) carries a
mortality between 21% to 33% of patients who are admitted to
the hospital.4
The cause of APT is not well understood. Amiodarone and
its metabolite, desethyl-amiodarone (DEAm), are amphiphilic
cations which accumulate in tissues, including the lung. It can
also infiltrate into the liver, skin, thyroid, and eye, which are
other common sites for adverse effects. In regards to pulmonary
toxicity, amiodarone can damage lung tissue directly via a
cytotoxic process and indirectly via immunological reactions,
supported by findings of CD-8-positive, cytotoxic T cells on
bronchoalveolar lavage often in combination with polymorphonuclear cells, increased production of toxic oxygen radicals, and
accumulation of phospholipids complexes which interfere with
normal cellular metabolic pathways.4, 5, 6
Risk factors for developing APT are increased age, pre-existing
lung disease, recent pulmonary insults, cardiopulmonary surgery
involving oxygen given at high concentrations, and dosages
greater than 400mg/day. It is more frequent in men and unusual
in patients younger than 40 years old, though rare case have been
described in children. Most amiodarone-induced pulmonary
manifestations are found to occur when the dosage exceeds
400mg/day administered for more than 2 months or when a
lower dosage is given for more than 2 years.2, 4, 5 However, APT
has been noted to occur in lower doses, albeit not as frequently.7
On average, pulmonary toxicity will develop in 5% to 15% of
patients who take 500mg/day or more and 0.1% to 0.5% who
take up to 200mg/day.4
The diagnosis of APT is one of exclusion including, but not
limited to heart failure, infectious pneumonia, organizing
pneumonia, pulmonary embolism, pulmonary infarct, and
malignancy. Onset of pneumonitis can develop at any time from
a few days after an initial loading dose to more than a decade
into treatment. Signs and symptoms are generally nonspecific
and include nonproductive cough, dyspnea, fever, weight loss,
and pleuritic chest pain.
Physical exam typically reveals bilateral rales. Patients with
APT may have nonspecific elevations in WBC, LDH, and
ESR. Amiodarone levels or DEAm have not been shown to be
predictive or diagnostic of APT. Pulmonary Function Testing
usually demonstrates typical changes of restrictive lung disease
and reduced diffusing capacity of the lung for carbon monoxide
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(DLCO), but most patients on amiodarone already have abnormal
PFTs.2
Chest radiograph may reveal diffuse or localized interstitial,
alveolar, or mixed opacities, and often presents with an
asymmetrical pattern. It can also be accompanied by pleural
thickening, especially if the opacities are localized in the
periphery, pleural effusion, or a mass (or masses). Acute
Respiratory Distress Syndrome (ARDS) can occur in patients
treated with amiodarone almost exclusively following thoracic
surgery. Diuresis that does not result in clearing of pulmonary
infiltrates should increase consideration of APT. 2,4 Most
progressing lung parenchymal disorders will eventually be
evaluated by a bronchoscopic evaluation.
In the setting of APT, on bronchoalveolar lavage, the presence
of foam cells with lamellar inclusions in patients chronically
exposed to amiodarone is a routine finding and dose not
indicate drug toxicity. However, the absence of foam cells makes
APT highly unlikely. A lung biopsy specimen of substantial size
maybe required to establish a more certain diagnosis and would
reveal parenchymal lung changes consistent with nonspecific
interstitial pneumonitis, organizing pneumonia, or diffuse
alveolar damage. It may also be useful in revealing another
potential cause of pulmonary injury, such as malignancy.
However, since ARDS can develop in patients on amiodarone
following thoracic surgery, open or thoracoscopic lung biopsies
are indicated when an accurate diagnosis is required early for
example, in patients in whom amiodarone cannot be held
without risks, if a diagnosis of pulmonary opacities is required
prior to heart surgery, and in patients who do not improve by
one to two months after drug cessation and initiation of steroids
to evaluate for other causes.4
In summary, one should consider the diagnosis of APT in the
presence of three or more of the following: new or worsening
symptoms or signs, new abnormalities on chest imaging, a
decline in the total lung capacity >15% or DLCO >20%, presence
of phospholipidosis in lung cells, a marked CD8+lymphocytosis
in lavage fluid, a lung biopsy that reveals diffuse alveolar damage,
organizing pneumonia, interstitial pneumonitis, or fibrosis, and
improvement in respiratory status following withdrawal of the
drug with or without steroid therapy.2
Treatment of APT consists primarily of discontinuing
amiodarone. This can, however, lead to an increased risk of
recurrence of life-threatening arrhythmias. One option is to
substitute another antiarrhythmic medicine though it may have
more negative inotropic and proarrhythmic effects. Another
option is to withhold amiodarone for several days, and then,
reduce the dosage to its lowest effective level, though pulmonary
toxicity has been noted to still occur at such doses. Other
options include radiofrequency ablation of a causative re-entry
mechanism and implantation of an automatic cardioverter
defibrillator.5 Despite the lack of controlled studies, there is

Case Reports

growing evidence that corticosteroids are beneficial. The current
recommendations are to start with an adequate dose of 0.75 to
1mg/kg of prednisolone or equivalent. The initial dosage should
then be maintained until definite clinical and radiographic
response is obtained, otherwise consider increasing the dose.
Tapering should be slow since recurrences have been described
up to eight months of cessation of therapy. A reasonable estimate
of duration of treatment is six months, more often one year, and
patients should be monitored carefully after discontinuation of
corticosteroids for possible recurrence. Clinical improvement
and clearing of pulmonary opacities typically require one to
three months. Toxic effects may continue and even temporarily
progress because of its persistence in the lung and accumulation
in fatty tissues leading to a long half-life of up to 45 days.2, 4, 5
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